Scarica l'app Stockscreener
1.21
5.22%
0.06
Dopo l'orario di chiusura:
1.22
0.01
+0.83%
Cardiol Therapeutics Inc Borsa (CRDL) Ultime notizie
Cardiol Therapeutics Inc (CRDL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
What's Going On With Cardiol Therapeutics Inc Class A Stock Tuesday? - Wealth Awesome
TradingKey - TradingKey
CRDL|Cardiol Therapeutics Inc|Price:1.180|Chg%:-0.050 - TradingKey
Cardiol Therapeutics Inc (CRDL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cardiol Therapeutics Inc (CRDL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cardiol Therapeutics Inc (CRDL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cardiol Therapeutics Inc. Class A Revenue Breakdown – SWB:CT9 - TradingView
Why Cardiol Therapeutics Inc Class A stock is sliding today - Wealth Awesome
Cardiol Therapeutics (CRDL) Gains 4.13% as Bullish Momentum Builds Above $1.23 SupportDouble EMA - dars.gov.et
What's Going On With Cardiol Therapeutics Inc Class A Stock Monday? - Wealth Awesome
CRDL Stock Price, Quote & Chart - ChartMill
Why Cardiol Therapeutics Inc Class A stock is skyrocketing today - Wealth Awesome
Cardiol Therapeutics (TSX:CRDL) Expands Visibility Across Healthcare Sector - Kalkine Media
Why Cardiol Therapeutics Inc Class A stock is rising today - Wealth Awesome
Cardiol Therapeutics Publishes Recurrent Pericarditis Phase II Data - t.co
H.C. Wainwright reiterates Cardiol Therapeutics stock Buy rating at $9 - Investing.com
H.C. Wainwright reiterates Cardiol Therapeutics stock Buy rating at $9 By Investing.com - Investing.com Nigeria
Cardiol Therapeutics’ Phase II Pericarditis Data in JAHA Bolsters Near-Complete Phase III MAVERIC Trial - TipRanks
Cardiol Publishes Phase II MAVERIC Data in the Journal of the American Heart Association - the deep dive
Cardiol publishes phase II pericarditis study in medical journal By Investing.com - Investing.com South Africa
CRDL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $9 - GuruFocus
Stocks in play: Cardiol Therapeutics Inc. - Yahoo! Finance Canada
Cardiol Therapeutics Inc. - Baystreet.ca
Cardiol publishes phase II pericarditis study in medical journal - Investing.com
Cardiol Therapeutics (NASDAQ: CRDL) publishes Phase II pericarditis data as Phase III nears full enrollment - Stock Titan
Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association - PR Newswire
CRDL SEC FilingsCardiol Therapeu 10-K, 10-Q, 8-K Forms - Stock Titan
Cardiol Therapeutics (CRDL) to Attend B. Riley Securities Summit in Boston - GuruFocus
Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit - 富途牛牛
Cardiol Therapeutics to Highlight CardiolRx Programs at B. Riley Mind, Muscle & Vision Summit - TipRanks
Cardiol Therapeutics (CRDL) to present CardiolRx™ pipeline at B. Riley Mind, Muscle & Vision Summit - Stock Titan
Why Cardiol Therapeutics Inc Class A stock is plummeting today - Wealth Awesome
ETFs Investing in Cardiol Therapeutics Inc. Class A Stocks - TradingView
Why Cardiol Therapeutics Inc Class A stock is gaining today - Wealth Awesome
Why Cardiol Therapeutics Inc Class A stock is tanking today - Wealth Awesome
CRDL Should I Buy - Intellectia AI
CRDL Q1 2026 Earnings: Narrower-than-Expected Loss as Cardiol Therapeutics Advances PipelineReturn On Equity - dars.gov.et
CRDL Q1 2026 Earnings: Narrower-Than-Expected Loss as Company Advances Clinical PipelineEstimate Uncertainty - DonanımHaber
CRDL Q1 2026 Earnings: Narrower-than-Expected Loss Signals Steady Clinical ProgressGAAP Earnings Report - dars.gov.et
Enterprise value to revenue forward of Cardiol Therapeutics Inc. – BOATS:CRDL - TradingView
Price to earnings forward of Cardiol Therapeutics Inc. Class A – TSX:CRDL - TradingView
Enterprise value to revenue forward of Cardiol Therapeutics Inc. Class A – TSX:CRDL - TradingView
Cardiol Therapeutics Inc. Class A Actuals & Estimates (TSX:CRDL) - TradingView
Cardiol Therapeutics Inc. Class A Actuals & Estimates (NEO:CRDL) - TradingView
CRDL Forecast — Price Target — Prediction for 2027 - TradingView
Cardiol Therapeutics Shareholders Back Board Slate and Auditor at 2026 AGM - TipRanks
A2PA9E Forecast — Price Target — Prediction for 2027 - TradingView
Strong shareholder support at Cardiol Therapeutics (CRDL) 2026 AGM as all directors elected - Stock Titan
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders - Finansavisen
3.50%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):